Every Form 4 that Cbdmd Inc (YCBD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow YCBD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full YCBD filings page.
Porter Jeffrey H reported acquisition or exercise transactions in this Form 4 filing.
cbdMD, Inc. director Jeffrey H. Porter reported receiving a grant of 1,572 restricted stock units of common stock on April 14, 2026 as compensation for his Board service. After this award, he directly holds 3,144 common shares and also controls sizable indirect holdings through several related entities.
Roe Kevin Charles reported acquisition or exercise transactions in this Form 4 filing.
cbdMD, Inc. director Kevin Charles Roe received a grant of 1,572 restricted stock units, each representing a right to one share of common stock, as compensation for Board service under the company’s 2021 or 2025 Equity Compensation Plan.
The award was approved by the Compensation, Corporate Governance and Nominating Committee and carries a stated price of $0.00 per unit, reflecting its nature as equity compensation rather than a market purchase. The restricted stock units vest quarterly on June 30, 2026, September 30, 2026, December 31, 2026 and March 31, 2027. Following this grant, Roe directly holds 26,707 shares or share-equivalent units of cbdMD common stock.
Swift Sibyl Nichole reported acquisition or exercise transactions in this Form 4 filing.
cbdMD, Inc. director Sibyl Nichole Swift received a grant of 1,572 shares of Common Stock on April 14, 2026 as an equity award, bringing her direct holdings to 4,145 shares. The award is in the form of restricted stock units, each representing a right to one share of common stock.
The restricted stock units were granted as compensation for her service on the Board of Directors under the company’s 2021 or 2025 Equity Compensation Plan. They vest in four quarterly installments on June 30, 2026, September 30, 2026, December 31, 2026, and March 31, 2027, and were approved in advance by the Compensation, Corporate Governance and Nominating Committee.
Sellers Bakari T. reported acquisition or exercise transactions in this Form 4 filing.
cbdMD, Inc. director Bakari T. Sellers reported an equity compensation grant of 1,572 shares of common stock in the form of restricted stock units at no cash cost per share. Following this award, his directly held equity position increased to 4,324 shares.
The restricted stock units vest in four quarterly installments on June 30, 2026, September 30, 2026, December 31, 2026 and March 31, 2027, aligning compensation with ongoing Board service under cbdMD’s 2021 or 2025 Equity Compensation Plan.
Stephen Scott G. reported acquisition or exercise transactions in this Form 4 filing.
cbdMD, Inc. director Stephen Scott G. received a grant of 1,572 restricted stock units as compensation for serving on the Board of Directors. Each unit represents one share of common stock and will vest in four quarterly installments on June 30, 2026, September 30, 2026, December 31, 2026, and March 31, 2027. Following this award, he holds 4,412 shares of common stock directly.
Raines William F III reported acquisition or exercise transactions in this Form 4 filing.
cbdMD, Inc. director William F. Raines III received a grant of 1,572 restricted stock units, each representing one share of common stock, as compensation for his service on the board. The grant carried no cash purchase price.
The restricted stock units vest in four quarterly installments on June 30, 2026, September 30, 2026, December 31, 2026, and March 31, 2027, under the company’s 2021 or 2025 Equity Compensation Plan. Following this award, Raines holds 13,676 shares of the company’s common stock directly.
cbdMD, Inc. insider Clark R. Crosnoe, a director, reported multiple sales of the company’s common stock on 12/17/2025, all held indirectly through investment vehicles and trusts. These transactions are disclosed on a Form 4 filed for a single reporting person.
The filing shows a sale of 461,725 shares at $2.3136 per share through CRC Investment Fund LP, leaving 361,400 shares beneficially owned through that entity. It also reports a sale of 69,875 shares at $2.3444 per share through NM 2018 Trust, with 56,875 shares remaining, and a sale of 19,101 shares at $2.3444 per share through AMC Legacy Trust, with 17,875 shares remaining.
The reporting person states that beneficial ownership of these securities is disclaimed except to the extent of his pecuniary interest, so the reported indirect holdings reflect economic exposure rather than a claim to full ownership of all shares.
cbdMD, Inc. reported an insider equity transaction for its CEO and CFO, who is also a director, on a Form 4. On 11/28/2025, the executive acquired 445,000 shares of common stock as restricted stock. After this grant, the executive beneficially owns 513,722 common shares in total.
The restricted shares were granted under cbdMD’s 2025 Equity Compensation Plan, and the filing notes that the vesting and issuance of these shares are subject to shareholder approval. The company also explains that the current beneficial ownership amount does not reconcile to the prior report because of a scrivener’s error.